AI-Assisted Technique Can Measure and Track Aging Cells
These senescent cells are known to play a key role in wound repair and aging-related diseases, such as cancer and heart disease, so tracking their progress, researchers say, could lead to a better understanding of how tissues gradually lose their ability to regenerate over time or how they fuel disease. The tool could also provide insight into therapies for reversing the damage.
Led by NYU Langone Health Department of Orthopedic Surgery researchers, the study included training a computer system to help analyze animal cells damaged by increasing concentrations of chemicals over time to replicate human aging. Cells continuously confronted with environmental or biological stress are known to senesce, meaning they stop reproducing and start to release telltale molecules indicating that they have suffered injury.
Publishing in the journal Nature Communications online July 7, the researchers' AI analysis revealed several measurable features connected to the cell's control center (nucleus), that, when taken together, closely tracked with the degree of senescence in the tissue or group of cells. This included signs that the nucleus had expanded, had denser centers or foci, and had become less circular and more irregular in shape. Its genetic material also stained lighter than normal with standard chemical dyes.
Further testing confirmed that cells with these characteristics were indeed senescent, showing signs that they had stopped reproducing, had damaged DNA, and had densely packed enzyme-storing lysosomes. The cells also demonstrated a response to existing senolytic drugs.
From their analysis, researchers created what they term a nuclear morphometric pipeline (NMP) that uses the nucleus's changed physical characteristics to produce a single senescent score to describe a range of cells. For example, groups of fully senescent cells could be compared to a cluster of healthy cells on a scale from minus 20 to plus 20.
To validate the NMP score, the researchers then showed that it could accurately distinguish between healthy and diseased mouse cells from young to older mice, age 3 months to more than 2 years. Older cell clusters had significantly lower NMP scores than younger cell clusters.
The researchers also tested the NMP tool on five kinds of cells in mice of different ages with injured muscle tissue as it underwent repair. The NMP was found to track closely with changing levels of senescent and nonsenescent mesenchymal stem cells, muscle stem cells, endothelial cells, and immune cells in young, adult, and geriatric mice. For example, use of the NMP was able to confirm that senescent muscle stem cells were absent in control mice that were not injured, but present in large numbers in injured mice immediately after muscle injury (when they help initiate repair), with gradual loss as the tissue regenerated.
Final testing showed that the NMP could successfully distinguish between healthy and senescent cartilage cells, which were 10 times more prevalent in geriatric mice with osteoarthritis than in younger, healthy mice. Osteoarthritis is known to progressively worsen with age.
'Our study demonstrates that specific nuclear morphometrics can serve as a reliable tool for identifying and tracking senescent cells, which we believe is key to future research and understanding of tissue regeneration, aging, and progressive disease,' said study senior investigator Michael Wosczyna, PhD. Wosczyna is an assistant professor in the Department of Orthopedic Surgery at the NYU Grossman School of Medicine.
Wosczyna says his team's study confirms the NMP's broad application for study of senescent cells across all ages and differing tissue types, and in a variety of diseases.
He says the team plans further experiments to examine use of the NMP in human tissues, as well as combining the NMP with other biomarker tools for examining senescence and its various roles in wound repair, aging, and disease.
The researchers say their ultimate goal for the NMP, for which NYU has filed a patent application, is to use it to develop treatments that prevent or reverse negative effects of senescence on human health.
'Our testing platform offers a rigorous method to more easily than before study senescent cells and to test the efficacy of therapeutics, such as senolytics, in targeting these cells in different tissues and pathologies,' said Wosczyna, who plans to make the NMP freely available to other researchers.
'Existing methods to identify senescent cells are difficult to use, making them less reliable than the nuclear morphometric pipeline, or NMP, which relies on a more commonly used stain for the nucleus,' said study co-lead investigator Sahil Mapkar, BS, Mapkar is a doctoral candidate at the NYU Tandon School of Engineering.
Funding for the study was provided by National Institutes of Health grant R01AG053438 and the Department of Orthopedic Surgery at NYU Langone.
Besides Wosczyna and Makpar, NYU Langone researchers involved in this study are co-lead investigators Sarah Bliss, and Edgar Perez Carbajal, and study co-investigators Sean Murray, Zhiru Li, Anna Wilson, Vikrant Piprode, Youjin Lee, Thorsten Kirsch, Katerina Petroff, and Fengyuan Liu.
About NYU Langone Health
NYU Langone Health is a fully integrated health system that consistently achieves the best patient outcomes through a rigorous focus on quality that has resulted in some of the lowest mortality rates in the nation. Vizient Inc. has ranked NYU Langone No. 1 out of 115 comprehensive academic medical centers across the nation for three years in a row, and U.S. News & World Report recently placed nine of its clinical specialties among the top five in the nation. NYU Langone offers a comprehensive range of medical services with one high standard of care across seven inpatient locations, its Perlmutter Cancer Center, and more than 320 outpatient locations in the New York area and Florida. With $14.2 billion in revenue this year, the system also includes two tuition-free medical schools, in Manhattan and on Long Island, and a vast research enterprise.
Media Contact
David March
212-404-3528
[email protected]
STUDY LINK
https://doi.org/10.1038/s41467-025-60975-z
STUDY DOI
10.1038/s41467-025-60975-z
View original content to download multimedia: https://www.prnewswire.com/news-releases/ai-assisted-technique-can-measure-and-track-aging-cells-302498942.html
SOURCE NYU Langone Health System
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2] STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLIA and XGEVA respectively, are commercially available in the U.S. Celltrion further expands its portfolio, delivering cost-effective and high-quality biologic medicines to wider range of patients in the U.S. JERSEY CITY, N.J., July 7, 2025 /PRNewswire/ -- Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively, are commercially available in the United States. STOBOCLO is available in 60 mg/mL injection and is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.[1] OSENVELT is available in 120 mg/1.7 mL (70 mg/mL) injection and is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy.[2] "We are pleased to have achieved a global settlement with Amgen regarding our denosumab biosimilars," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "We are proud to introduce our denosumab biosimilars to the U.S. market, offering patients and healthcare professionals a valuable alternative treatment option. Building on our strong heritage in biosimilars, Celltrion remains committed to being a trusted partner for both patients and physicians, while contributing to the overall sustainability of healthcare systems." STOBOCLO and OSENVELT are supported by Celltrion's comprehensive patient support programs designed to help empower patients to navigate their treatment journeys. Celltrion offers a suite of resources, including the Celltrion CONNECT® Patient Support Program and the Celltrion CARES™ Co-pay Assistance Program. Patients who are uninsured may be able to receive STOBOCLO and OSENVELT at no cost. Visit and to learn more. Celltrion's biosimilars portfolio covers the areas of immunology, oncology, gastroenterology, allergy, and endocrinology. About STOBOCLO® (denosumab-bmwo) STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. INDICATIONS STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer of glucocorticoid-induced osteoporosis in men and women at high risk for fracture to increase bone mass in women at high risk for fracture receiving an adjuvant aromatase inhibitor therapy for breast cancer IMPORTANT SAFETY INFORMATION WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities. The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD. STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab. Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia. Drug Products with Same Active Ingredient: Do not use with other denosumab products. Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis. Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO. Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop. Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur. Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops. Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes. Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products. Most common Adverse Reactions: In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis. Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache. Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials. For more information, see Full Prescribing Information. About OSENVELT® (denosumab-bmwo) OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. INDICATION OSENVELT® (denosumab-bmwo) is indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. IMPORTANT SAFETY INFORMATION Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products. Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly. Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT. Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake. Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis. Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation. Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT. Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose. Most common Adverse Reactions: Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea. In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity. Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea. For more information, see Full Prescribing Information. About Celltrion, Inc. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook. About Celltrion USA Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec), as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit and stay updated with our latest news and events on our social media - LinkedIn. FORWARD-LOOKING STATEMENT Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. Trademarks STOBOCLO® and OSENVELT® are registered trademarks of Celltrion, and XGEVA® are registered trademarks of Amgen Inc. References [1] STOBOCLO U.S. prescribing information (2025) [2] OSENVELT U.S. prescribing information (2025) US-CT-P41-25-00006 For further information please contact:Andria Arenaaarena@ 516-578-0057 View original content to download multimedia: SOURCE Celltrion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Governor reveals ‘Make Oklahoma Healthy Again' plan with RFK for bans on soda, red dye
Gov. Kevin Stitt, center, pens his name during a ceremonial signing of an executive order to "Make Oklahoma Healthy Again," as Robert F. Kennedy Jr., right, the nation's secretary of health, and other supporters look on Thursday, June 26, 2025. (Photo by Janelle Stecklein/Oklahoma Voice) OKLAHOMA CITY — In a move quickly panned by licensed health care providers, Gov. Kevin Stitt announced Thursday that he planned to 'Make Oklahoma Healthy Again' by urging state agencies to stop supporting public water fluoridation, removing red food dyes from school and prison meals, and by asking the federal government to approve a request that bans food stamp recipients from purchasing soda and candy. Stitt's pledge came minutes after Robert F. Kennedy Jr., the nation's secretary of Health and Human Services, criticized the state for having the 47th worst health outcomes during a raucous 'MOHA' kickoff rally that drew hundreds of people to the state Capitol. Oklahoma has become the latest conservative state to submit a waiver to the U.S. Department of Agriculture that seeks to ban the state's Supplemental Nutrition Assistance Program recipients from using their benefits to buy sodas, candies and other confectionery items, Stitt said. Tax dollars will no longer 'continue to fund foods that are making people sick,' he said. State officials will also work with the U.S. Department of Agriculture to find more ways to promote healthly eating and to make food stamp funding go further. 'Eating healthy foods today is going to reduce health care spending and dietary related illnesses later on in life,' Stitt said. The Republican governor also said he's instructed the Oklahoma State Department of Health to stop recommending fluoride in public water. 'Cities and water districts, they can still choose to do what they want, based on their constituents and the science, but it's no longer going to be a recommendation for the state health department,' Stitt said. And Stitt said he's instructed all state agencies that provide meals to Oklahomans to discontinue their use of artificial dyes. He also plans to convene an advisory counsel to recommend other changes that can improve health outcomes across the state. Stitt's plans immediately faced criticism from licensed medical providers who showed up en masse at the rally, holding signs reading 'Support Evidence-Based Health Care', 'Encourage Immunizations' and 'Protect Medicaid.' Dr. Steven Crawford, chair of the Oklahoma Alliance for Healthy Families, said it would be 'disastrous' for children's health to remove fluoride from water. 'We do know that appropriate public water fluoridation prevents cavities,' he said. 'And how do you help children get better nutrition when they don't have adequate dentition or teeth to be able to eat the food? So I am so sad that the governor is advocating removing appropriate fluoride from public water.' Crawford, who practices medicine in Oklahoma City, said fluoridation of public water and immunizations are two of the major health benefits over the past century and have been critical to improving the state's and nation's health outcomes. He said removing candy and sugary drinks from the list of approved food stamp items isn't inappropriate, but Stitt neglected to mention that many recipients already don't get enough resources to be able to buy healthy foods. The governor also didn't discuss increasing food stamp funding to ensure children are getting adequate nutrition, particularly during the summer months when they are not eating at school, he said. Kennedy, who participated in a staged, ceremonial executive order signing with Stitt, praised the governor's actions. 'I am so gratified by these actions that are being taken by Gov. Stitt to make Oklahoma healthy again,' Kennedy said. Spectators heckled Kennedy throughout his speech that focused on America's soaring rates of obesity, diabetes and autism, declines in the nation's fertility rates and a drop in American teenage boys' testosterone levels. Kennedy, who has been criticized as being a vaccine skeptic, did not mention immunizations during his address. At one point, a state trooper could be seen escorting two bystanders from the crowd after one began shouting something unintelligible at Kennedy. A spokesperson for the Oklahoma Highway Patrol did not immediately respond to a request for comment about the encounter. Kennedy said when people ask him if he's taking soda and sugary drinks away from the Americans, he tells them that they should have the right to drink a bottle of soda. 'We live in a country where we have individual freedom,' he said. The federal government just should not be paying for it, he said. 'We're paying for them at the front end by buying soda for the poorest Americans, and then we're paying for it (on) the back end with this diabetes, for Medicaid and Medicare,' Kennedy said. 'And it doesn't make any sense. We are poisoning the American people.' He said electing leaders like Stitt will change the way we do things in the U.S. to give American children a better chance of growing up healthy. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
an hour ago
- Yahoo
Children in the U.S. Are Dying at a Higher Rate than Kids in Similar Countries, Study Says
A new study published by the Journal of the American Medical Association suggested that American children are in worse health than their counterparts in other countries Babies are 1.78 times more likely to perish, and children aged 1 to 19 are 1.8 times more likely to die than those in comparable countries Author Dr. Chris Forrest pointed out that the worrying trends are like a "proverbial canary in the coal mine," pointing to a larger problem within AmericaA new study shed light on a worrying trend in the health of American children. In a Monday, July 7 study published by the Journal of the American Medical Association (JAMA), research suggested that American children are in worse health than those growing up in other developed countries. Additionally, they are progressively less healthy than they were in previous years. The study examined trends in the health of children between 2007 and 2023. It found that in the U.S., "children's health has deteriorated across a broad spectrum of indicators." Data and trends between 2007 and 2022 suggest that infants are 1.78 times more likely to die in the U.S. than in other countries of a similar standing. Children between the ages of 1 and 19 were also 1.8 times more likely to die than their counterparts in other countries. In the latter group, there was a marked difference in the likelihood of dying from "firearm-related incidents" and "motor vehicle crashes," with American children dramatically more likely to perish as a result of these avoidable tragedies. In perspective, this amounts to approximately 54 more children dying per day in America, per the study. The findings come after deaths in the U.S. were in line with other countries in the 1960s. The study also suggested that American children were 14% more likely to suffer a chronic condition than their counterparts. The likelihood of being diagnosed with a chronic condition also increased from 39.9% to 45.7% in America between 2011 and 2023. Examples of chronic issues that children are now battling include the likes of "depression, anxiety and loneliness increased, as did rates of autism, behavioral conduct problems, developmental delays, speech language disorders and attention-deficit hyperactivity disorders." 'I think we all should be disturbed by this,' Dr. Chris Forrest, a professor of pediatrics at Children's Hospital of Philadelphia and director of the Applied Clinical Research Center, told CNN. 'Kids in this country are really suffering.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Speaking to the outlet, Forrest noted that he has seen a change in his patients since he started practicing medicine in the '90s. He attributed that to a variety of elements, saying that it comes together to create "a very toxic environment." While the Make America Healthy Again Commission, fronted by U.S. Secretary of Health and Human Services Robert F. Kennedy has targeted chemicals in food and elsewhere as a cause for America's worsening health, Forrest said that the problem runs much deeper. "It's not just the chemicals. It's not just the food and the iPhones. It's a much broader. It's much deeper. It's what we call the developmental ecosystem, and it makes it very challenging to change it,' Forrest told CNN. 'That's a hard answer for people who want a pithy message that tells them how to fix the issues. It's about where they're growing up, where they're going to school, they're playing, where their families live, their neighborhoods, and it's not just one population. It's the whole nation that needs help.' Another element that he highlighted was that "women are also suffering in this country," suggesting that children are being born into already sickening households. Citing the research, he said, 'This means the same kid born in this country is much more likely to die than if they were born in Germany or Denmark. Why are we allowing this to happen?' For Forrest, the research is comparable to "the proverbial canary in the coal mine." "When [children's] health is deteriorating, that means the foundation of our nation is also deteriorating," he concluded. Read the original article on People
